LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

68.64 0.48

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

68.06

Maxim

69.53

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	24.112 50.102
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+17.8% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	501M 8.2B
Deschiderea anterioară	68.16
Închiderea anterioară	68.64

Sentimentul știrilor

By Acuity

12%

88%

13 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 mai 2026, 16:52 UTC

Evenimente importante

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q EPS $11.61 >WEBC

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q Sales $179.6M >WEBC

26 mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 mai 2026, 20:58 UTC

Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

26 mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

17.8% sus

Prognoză pe 12 luni

Medie 80.48 USD 17.8%

Maxim 96 USD

Minim 66.41 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

13 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.